Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7197882 | 0.98 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL7201771 | 0.93 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL7199322 | 0.91 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL7195296 | 0.90 | EDNRA (0.82) | EDNRBEDNRA | |
| SCHEMBL7193647 | 0.90 | EDNRB (0.96) | EDNRBEDNRA | |
| SCHEMBL7194837 | 0.89 | EDNRA (0.82) | EDNRBEDNRA | |
| SCHEMBL7194658 | 0.89 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL7196218 | 0.88 | EDNRA (0.79) | EDNRBEDNRA | |
| SCHEMBL7199326 | 0.88 | EDNRA (0.78) | EDNRBEDNRA | |
| SCHEMBL7990476 | 0.88 | EDNRA (0.78) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596719-B1 | Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the | ACTELIO PHARMACEUTICALS LTD. (CH) | 2003-07-22 | — | — | US | claimed |
| EP-1137642-A1 | BIS-SULFONAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2001-10-04 | — | — | EP | claimed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | claimed |
| US-6596719-B1 | Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the | ACTELIO PHARMACEUTICALS LTD. (CH) | 2003-07-22 | — | — | US | disclosed |
| EP-1137642-A1 | BIS-SULFONAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |